By Tony Fong

NEW YORK (GenomeWeb News) – In the midst of a $5 million financing round, microfluidics company Biocept is looking to launch its first diagnostic test, as it embarks on "redefining what a circulating tumor cell is."

Thirteen years after its founding, and following changes in its technology focus and other adaptations, the company plans to soon launch its first diagnostic test, directed at breast cancer, Biocept President and CEO Stephen Coutts told GenomeWeb Daily News.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.